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Abstract
Dogs with mucopolysaccharidosis VII (MPS VII) were injected intravenously at 2–3 days of age with a
retroviral vector (RV) expressing canine β-glucuronidase (cGUSB). Five animals received RV alone, and two
dogs received hepatocyte growth factor (HGF) before RV in an attempt to increase transduction efficiency.
Transduced hepatocytes expanded clonally during normal liver growth and secreted enzyme with mannose
6-phosphate. Serum GUSB activity was stable for up to 14 months at normal levels for the RV-treated dogs,
and for 17 months at 67-fold normal for the HGF/RV-treated dog. GUSB activity in other organs was
1.5–60% of normal at 6 months for two RV-treated dogs, which was likely because of uptake of enzyme from
blood by the mannose 6-phosphate receptor. The body weights of untreated MPS VII dogs are 50% of normal
at 6 months. MPS VII dogs cannot walk or stand after 6 months, and progressively develop eye and heart
disease. RV- and HGF/RV-treated MPS VII dogs achieved 87% and 84% of normal body weight, respectively.
Treated animals could run at all times of evaluation for 6–17 months because of improvements in bone and
joint abnormalities, and had little or no corneal clouding and no mitral valve thickening. Despite higher GUSB
expression, the clinical improvements in the HGF/RV-treated dog were similar to those in the RV-treated
animals. This is the first successful application of gene therapy in preventing the clinical manifestations of a
lysosomal storage disease in a large animal.
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Dogs with mucopolysaccharidosis VII (MPS VII) were injected in-
travenously at 2–3 days of age with a retroviral vector (RV)
expressing canine -glucuronidase (cGUSB). Five animals received
RV alone, and two dogs received hepatocyte growth factor (HGF)
before RV in an attempt to increase transduction efficiency. Trans-
duced hepatocytes expanded clonally during normal liver growth
and secreted enzyme with mannose 6-phosphate. Serum GUSB
activity was stable for up to 14 months at normal levels for the
RV-treated dogs, and for 17 months at 67-fold normal for the
HGFRV-treated dog. GUSB activity in other organs was 1.5–60%
of normal at 6 months for two RV-treated dogs, which was likely
because of uptake of enzyme from blood by the mannose 6-phos-
phate receptor. The body weights of untreated MPS VII dogs are
50% of normal at 6 months. MPS VII dogs cannot walk or stand
after 6 months, and progressively develop eye and heart disease.
RV- and HGFRV-treated MPS VII dogs achieved 87% and 84% of
normal body weight, respectively. Treated animals could run at all
times of evaluation for 6–17 months because of improvements in
bone and joint abnormalities, and had little or no corneal clouding
and no mitral valve thickening. Despite higher GUSB expression,
the clinical improvements in the HGFRV-treated dog were similar
to those in the RV-treated animals. This is the first successful
application of gene therapy in preventing the clinical manifesta-
tions of a lysosomal storage disease in a large animal.
The mucopolysaccharidoses (MPS) are lysosomal storagediseases (LSD) that result from deficient activity of enzymes
that degrade glycosaminoglycans (GAGs) (1, 2). The overall
incidence of MPS is 1:27,000 live births (3). MPS VII (Sly
syndrome) is due to deficient -glucuronidase (GUSB; EC
3.2.1.31) activity and results in growth retardation, mobility
problems, dysostosis multiplex, facial dysmorphia, hepatospleno-
megaly, corneal clouding, cardiac valvular abnormalities, and
mental retardation (4). MPS VII dogs are homozygous for an
arginine to histidine substitution at amino acid 166 in the canine
GUSB (cGUSB) protein (5, 6). Features in MPS VII dogs
resemble those in humans, except mental retardation is difficult
to assess, and hepatosplenomegaly is less severe.
The clinical manifestations of LSD can be reduced by enzyme
replacement therapy (ERT), which involves i.v. injection of
enzyme. Enzyme that contains mannose 6-phosphate (M6P) can
be internalized via the M6P receptor (M6PR) present on the
surface of most cells (7, 8). ERT has been therapeutic in mice
with MPS VII (reviewed in ref. 9), large animals with MPS
(10–12), and humans with LSD (13–15). The rationale for
hepatic gene therapy is that the liver will continuously secrete
GUSB with M6P into the blood, because most cells that produce
functional GUSB secrete some enzyme that is phosphorylated.
We and others have demonstrated that Moloney murine
leukemia virus (MLV)-based retroviral vectors (RV) can stably
express proteins from the liver in rodents (reviewed in ref. 16).
Although efficient transfer into hepatocytes of adults by using an
MLV-based RV requires induction of replication with hepato-
cyte growth factor (HGF) (17) or other methods, the rapid liver
growth allowed transduction to occur without any stimulus for
hepatocyte replication in newborn mice (18) and dogs (19). We
report the clinical improvements seen in six MPS VII dogs that
were transduced with a cGUSB-expressing RV as neonates and
followed for 6–17 months.
Materials and Methods
hAAT-cGUSB-WPRE contains the human 1-antitrypsin pro-
moter upstream of the canine GUSB cDNA (19). For the
RV-treated dogs, MPS VII dogs were injected with four doses of
a 5-ml bolus of hAAT-cGUSB-WPRE over 1–2 min at 4-h
intervals via an external jugular catheter at 2–3 days after birth
as described (19) and summarized in Table 1. For the HGF
RV-treated dogs, eight equal doses of human HGF (20) were
given every 3 h (cumulative dose 2.5 mgkg) beginning at 2 days
after birth. Beginning 3 h after the last dose of HGF, they each
received four doses of RV (5 ml every 4 h) via the i.v. catheter.
Analysis of Animals. Dogs were maintained at the School of
Veterinary Medicine University of Pennsylvania under National
Institutes of Health and U.S. Department of Agriculture guide-
lines for the care and use of animals in research. Liver biopsies
were performed as described (19). Radiographs and aspiration
of synovial joint f luid and aqueous humor were performed after
i.m. injection of 0.02 mgkg of atropine (Phoenix Pharmaceu-
tical, St. Joseph, MO) and 0.1 mgkg of hydromorphone (Elkins-
Sinn, Cherry Hill, NJ), and an i.v. injection of 2 mgkg of
propofol (Abbott). For the ocular examination, the pupils were
dilated with 1% tropicamide (Mydriacyl 1%, Alcon Laborato-
ries, Ft. Worth, TX). Evaluations of radiographs, eyes, and
echocardiograms were done by a radiologist (V.W.K.), an oph-
thalmologist (G.A.), and a cardiologist (M.S.), respectively, who
were blinded to the genotype and treatment of the animals.
Euthanasia was performed using 80 mgkg of sodium pentobar-
bital (Veterinary Laboratories, Lenexa, KS) in accordance with
American Veterinary Medical Association guidelines, and tissue
samples were frozen immediately on dry ice. Dog M1339 died
while under propofol anesthesia during removal of cerebrospinal
f luid. He appeared to be in good health before the procedure.
Dogs were perfused with two liters of cold saline before the
collection of tissues. Averages  the standard error of the mean
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(SEM) were calculated for all values, and comparisons were
between two groups by using the Student’s t test.
Analysis of Serum and Organs. GUSB histochemical staining of
liver was performed on 8-m frozen sections by using conditions
that reduced the activity, as detailed in ref. 19. GUSB activity
was determined by incubating samples with 4-methylumbelliferyl
-D-glucuronide (Sigma) for 1–16 h, and measuring fluorescence
(17). One unit of enzyme produces 1 nmol of product in 1 h. For
organ extracts, activity was normalized to the protein concen-
tration (Bradford assay kit, Bio-Rad). The percentage of trans-
duced hepatocytes was calculated as detailed (19). To determine
the percentage of M6P-containing enzyme, 500 l of serum was
loaded onto a 1 ml column containing the cationic independent
M6PR coupled to Sepharose (7). The column was washed with
5 ml of PBS, then with 5 ml of 5 mM glucose 6-phosphate in PBS,
and M6P-containing proteins were eluted with 5 ml of 10 mM
M6P in PBS. The total enzyme activity in each fraction was then
determined.
Results
Five ‘‘RV-treated’’ MPS VII puppies received an i.v. injection of
amphotropic RV within 3 days after birth (Table 1), as reported
(19). Two ‘‘HGFRV-treated’’ MPS VII dogs received human
HGF, which induces replication of canine hepatocytes (21),
followed by a 3-fold higher dose of RV than was given to the
Table 1. Summary of gene transfer and clinical effects in treated and control dogs
Dog*
Dose of RV,
rfukg, and
time of first
dose†
Percent liver
cells
transduced
at 4M‡
Liver GUSB,
unitsmg,
at 4M§
Serum GUSB,
unitsml¶
Percent serum
GUSB with M6P
Evaluation of gait, cornea,
and heart at the indicated
time after birth**
RV-treated MPS VII dogs
M1312 Cisco male 3.5  109 at 48 h 3.1% 178 166 at 6M 27.4  9.3% (n  3) Ran with stiff gait, short stride,
and a limp at 6M
M1328 Roy male 3.6  109 at 48 h 2.5% 183 429 at 14M 8.4  3.7% (n  2) Runs with almost normal gait,
mild right hind leg lameness,
and mild bilateral tarsal
valgus at 14M; slight corneal
clouding at 8M; mild MR at
9M, but no murmur or MV
thickening
M1332 Dale female 3.7  109 at 48 h 2.0% 89 76 at 14M 19.7  1.6% (n  2) Runs with almost normal gait at
14M; no corneal clouding at
8M; no MV disease at 9M
M1337 Penny female 3.3  109 at 72 h 4.4% 317 294 at 14M 11.7  2.7% (n  2) Runs with almost normal gait at
14M; has mild spina bifida
occulta; no corneal clouding
at 8M; no MV disease at 9M
M1339 Sky King male 3.0  109 at 72 h 2.1% 144 132 at 6M 8.3  1.3% (n  2) Ran with stiff gait, short stride,
a limp, and severe tarsal and
carpal valgus at 6M
HGFRV-treated MPS VII dogs
M1287 Preston male 12  109 at 67 h 19.4% 2830 18,039 at 17M 24.3  7.5% (n  2) Runs with moderate tarsal
valgus, stiff gait, short stride,
a limp, and hind legs close
together at 17M; has mild
spina bifida occulta; no
corneal clouding at 11M; no
MV disease at 12M
M1288 male 7.9  109 at 67 h 10.1% at 5D 863 at 5D 8,617 at 5D 4.5% at 5D ND as he was killed at 8 days
Normal dogs
NA NA 0 475.1  40.4
(n  11)
269  16.6
(n  10)
36.8  3.5% at 3M
(n  7); 5.5  1.5%
at 5D
Run normally with an occasional
animal with a stiff gait due to
hip dysplasia; no corneal
clouding; no MV disease
Untreated MPS VII dogs
NA NA 0 0.3  0.1
(n  3)
0.55  0.05
(n  6)
ND Cannot stand or walk by 6
months of age; corneal
clouding present by 4M; MV
murmur, MV thickening, and
MR present by 9 months
*The number, name, and sex of each treated dog. NA, not applicable.
†The cumulative dose of RV in red-forming units (rfu)kg and the age after birth in hours of the first dose of RV. The HGFRV-treated dogs received HGF during
the 24 h prior to RV injection, as detailed in the methods section.
‡The percentage of hepatocytes that were transduced was determined at 4 months (4M) after transduction for most animals. Evaluation was at 5 days (5D) after
treatment for M1288.
§The GUSB activity in liver homogenates was determined at 4M after transduction unless otherwise stated.
¶The GUSB activity in serum at the last time of analysis, which is indicated in months (M) or days (D) after transduction.
The percentage of the total GUSB in serum that bound to a M6PR column and eluted with M6P on the indicated number (n) of samples collected at 1–6 months
after transduction unless otherwise stated. ND, not determined.
**The gait, degree of corneal clouding, and mitral valve (MV) disease at the indicated time in months (M) after birth. Normal MV means no murmur of mitral
valve regurgitation (MR) or echocardiographic evidence of MR or MV thickening.
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RV-treated dogs (Table 1). Histochemical staining for GUSB
demonstrated that untreated affected dogs had no detectable
activity (not shown), whereas activity was low in hepatocytes
from normal animals (Fig. 1A). An average of 2.8%  0.4%
(SEM) of hepatocytes from the RV-treated dogs had high GUSB
activity at 4 months after treatment, and were presumably
transduced (19). For the two HGFRV-treated dogs, 10.1% and
19.4% of all hepatocytes were transduced at 1 week (Fig. 1B) and
4 months (Fig. 1 C and D), respectively. The large clusters
present at 4 months likely derived from clonal expansion of
transduced hepatocytes during normal growth. At 4 months,
GUSB activity in liver homogenates was 182  38 unitsmg
(38% of normal) for RV-treated dogs, and 2,830 unitsmg
(6-fold normal) for an HGFRV-treated dog (Fig. 1E). Al-
though the percentage of transduced hepatocytes was 7-fold and
the liver GUSB activity 12-fold higher for the HGFRV-treated
than for the RV-treated dogs at 4 months, only one HGFRV-
treated dog was evaluated, and it is unclear whether the higher
vector dose or the preadministration of HGF was responsible for
the higher expression. Previously, prior administration of HGF
resulted in a very modest and statistically insignificant increase
in the percentage of neonatal hepatocytes that were transduced
with an RV, although small numbers of animals were analyzed
(19). Studies in additional animals will need to be performed to
determine whether HGF potentiates transduction of hepato-
cytes from neonatal MPS VII dogs with an MLV-based vector.
We next tested whether the liver secreted enzyme with M6P.
Serum GUSB activity was 195  36 unitsml (73% of normal)
for the RV-treated group at 6 months (Fig. 1F) and was stable
thereafter in three dogs (Table 1). For the HGFRV-treated
dogs, serum GUSB activity rose rapidly, and was 2,203  51
unitsml (8.3-fold normal) at 2 days and 8,861  244 unitsml
(33-fold normal) at 5 days. The one HGFRV-treated animal
that was followed longer maintained stable levels of GUSB
activity at 18,039 unitsml (67-fold normal) at 17 months. In
normal dogs, 37%  4% of the serum GUSB contained M6P
(Fig. 1G). Although this value was significantly lower (P 0.001)
for the RV-treated dogs, 16%  3% of their serum GUSB was
mannose 6-phosphorylated. For the HGFRV-treated dog, 24%
of the serum GUSB contained M6P. GUSB activity was present
in all organs at 1.5% to 60% of normal values for two RV-treated
dogs that were killed at 6–7 months after transduction (Fig. 1H).
Activity was probably not due to contamination with blood,
because the animals were perfused with saline before the
collection of tissues. The activity in spleen may derive in part
from expression, because RV DNA sequences were identified in
the spleen shortly after i.v. injection of an MLV-based RV into
newborn dogs (19). However, activity in other organs was likely
due to uptake from blood, because in our previous study 0.6%
or fewer of the cells from other organs were transduced after i.v.
injection of a higher dose of RV than was used here (19).
Growth, Gait, Joints, and Bones. The average body weight of un-
treated affected dogs was only 50% that of normal littermates at 6
months (Fig. 2A; P  0.0001 for affected vs. normal), whereas the
weights of RV-treated dogs were 87% of normal (not significant for
RV-treated vs. normal), and 1.7-fold that of untreated affected dogs
(P  0.003 for RV-treated vs. untreated dogs). The weight of the
Fig. 1. Expression and secretion of GUSB. (A–D) In situ GUSB staining of liver sections. Frozen liver sections were stained for GUSB activity (red cytoplasm) and
counterstained with hematoxylin (blue nuclei). (A) Normal. Very little enzyme activity was present in hepatocytes after 1 h of staining. (Original magnification:
60.) (B) HGFRV-treated MPS VII dog at 5 days after treatment. The MPS VII dog M1288 was treated with HGF before the injection of RV as detailed in Table
1, and killed at 5 days after transduction. The arrows indicate transduced hepatocytes with high levels of enzyme activity in a 1-h stain. (Original magnification:
60.) (C and D) HGFRV-treated dog at 4 months. Liver biopsy of the HGFRV-treated dog M1287 4 months after transduction. The arrows indicate clusters of
hepatocytes with high levels of enzyme activity after a 25-min stain. (Original magnification: C, 10; D, 60.) (E) Liver GUSB. Livers from homozygous normal
(N; n  9), untreated affected MPS VII dogs (A; n  3), RV-treated MPS VII dogs at 4 months (RV; n  5), or an HGFRV-treated MPS VII dog (HGFRV; n  1) at
4 months after transduction were homogenized and the GUSB-specific activity determined. The activity relative to that of homozygous normal dogs was
determined and plotted as the average  SEM. The P value for comparison of activity in affected and RV-treated dogs is shown. (F) Serum GUSB. Serum GUSB
activity was measured 6 months after transduction and the activity relative to that in homozygous normal dogs was determined. (G) Percent GUSB with M6P.
The percentage of GUSB that contained M6P for serum samples obtained at 1–6 months after birth for normal (N; n 7), RV-treated dogs (RV; n 11 because
of analysis of samples at two or three times for each animal), or HGFRV-treated dogs (HGFRV; n 2). (H) Organ GUSB activity. Organs from two homozygous
normal dogs (black bars), one untreated affected dog (red bars), and two RV-treated MPS VII dogs (M1312 and M1339; green bars) at 6 months after birth were
homogenized and the GUSB specific activity determined. KidneyM is kidney medulla, KidneyC is kidney cortex, and BM is bone marrow.
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only HGFRV-treated dog evaluated was 84% of normal at 6
months. Untreated affected dogs are unable to walk by 6 months,
primarily because of orthopedic abnormalities, because neurolog-
ical examinations are normal. In contrast, all transduced dogs
remained able to run throughout the study period (6–17 months;
see Movie 1, which is published as supporting information on the
PNAS web site, www.pnas.org, and Table 1). However, some
treated animals had tarsal valgus (turning out of the hind foot) and
mild to moderate gait abnormalities.
On physical examination, all untreated affected dogs had effu-
sions in their knee and elbow joints by 6 months, whereas the
treated dogs had no effusions throughout the study period. Synovial
fluid from the knee contained 5.4  2 unitsmg (60% of normal)
of GUSB activity for the RV-treated dogs and 121.4 unitsmg
(13-fold normal) for the HGFRV-treated dog (Fig. 2B). Radio-
graphs of the hind leg of affected dogs at 6 months of age
demonstrated that the femoral head and the distal femur have bony
mottling that result from epiphyseal dysplasia, the femoral head is
luxated (separated) from the acetabulum, the femur is curved and
appears shorter than in the normal animals, and the patella is
medially luxated (Fig. 2C). Radiographs of the RV- and HGF
RV-treated dogs had fewer abnormalities than the untreated
affected dogs (Fig. 2 C and D), although some manifestations of
orthopedic disease in the hind leg were not prevented, and there
was no amelioration of abnormalities in the cervical spine (not
shown). These orthopedic improvements are likely to be responsi-
ble for the ability of the treated MPS VII dogs to walk.
Ocular Disease. Lysosomal storage pathology occurs in the corneal
stroma of affected dogs, which results in a cloudy ground-glass
appearance (not shown) and blurring of the fundus image (Fig.
3A) by 4 months. In contrast, the fundi appeared sharp in all
three RV-treated dogs and one HGFRV-treated dog evaluated
at 8–11 months (Fig. 3A), and little or no corneal clouding was
present (not shown). The prevention of corneal clouding is likely
due to uptake of enzyme from blood via the prelimbic capillaries
by the corneal stromal cells (9, 22). The aqueous humor from
RV-treated dogs had 0.7 unitsml of GUSB activity (10% of
normal; Fig. 3B), whereas the aqueous humor from the HGF
RV-treated dog had 4 unitsml (56% of normal). Enzyme in the
aqueous humor might reduce lysosomal storage material in the
endothelium of the cornea (23).
Heart Disease. Accumulation of glycosaminoglycans (GAGs) in
the heart values can result in cardiac disease, which is a major
cause of death in MPS patients (1). By 8–9 months, 50% of
untreated MPS VII dogs had murmurs of mitral valve regurgi-
tation (MR), most had echocardiographic evidence of MR, and
all had mitral valve thickening (Fig. 4). For the three RV-treated
dogs evaluated at 9 months, none had murmurs, only one had
mild MR, and none had mitral valve thickening. The HGFRV-
treated MPS VII dog had no cardiac abnormalities at 12 months.
All treated dogs evaluated had normal thickness of the tricuspid,
aortic, and pulmonary valves, no aortic valve insufficiency, and
the aortic diameter was within normal limits. These parameters
are usually abnormal in untreated affected dogs by this age (24).
Discussion
MPS VII and related disorders might be treated in three ways:
(i) ERT; (ii) bone marrow transplantation (BMT); and (iii) gene
therapy. ERT has reduced many of the clinical manifestations of
MPS in animals and humans (9–13), but is inconvenient to
administer and is extremely expensive. BMT has lessened the
clinical manifestations of MPS VII in mice (reviewed in ref. 9),
and MPS in large animals (24–26) and humans (27–29), but has
substantial risks for patients and a compatible donor is often not
Fig. 2. Effect of RV-mediated gene therapy on growth, joints, and bones. (A) Growth curve. The body weights of six normal, five untreated MPS VII, five
RV-treated MPS VII, and one HGFRV-treated MPS VII dogs from the same three litters were plotted as the average SEM. (B) Synovial fluid GUSB. Synovial fluid
was aspirated from the knee joint at 6–8 months after birth for normal (N; n  7), 6–8 months for affected (A; n  6), 6–8 months for RV-treated (RV; n  7
because of inclusion of fluid from both knees in some animals), and 10 months for HGFRV-treated (HGFRV; n  1) dogs. The averages  SEM are shown.
(C) Radiographs of the hind limb. Radiographs were obtained from a normal dog at 8 months (8m), an untreated affected dog at 6 months, an RV-treated MPS
VII dog (RV; M1332) at 7 months, and the HGFRV-treated MPS VII dog (HGFRV; M1287) at 10 months. FH, femoral head; E, epiphysis; A, acetabulum; F, femur;
P, patella. (D) Quantitation of radiograph changes. Radiographs of the upper leg from two normal dogs at 6–7 months, three untreated affected MPS VII dogs
at 6–7 months, four RV-treated MPS VII dogs at 6–7 months, and one HGFRV-treated MPS VII dog at 10 months were evaluated by a radiologist and scored as
0 (normal), 1 (mildly to moderately abnormal), or 2 (markedly abnormal), and plotted as the average  SEM. Bars are shaded and appear in the same order as
in B. The amount of curving of the femur (Femur Curve), effusion in the knee joint (Knee Effus.), luxation of the hip and of the patella, epiphyseal (E.) dysplasia
of the proximal (Prox) and distal femur, and articular erosion of the proximal and distal femur are shown. The P values were obtained from statistical comparisons
between values for untreated affected and RV-treated dogs.
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available. Gene therapy of hematopoietic cells has improved
pathology in mice (30, 31), but has not been effective in large
animals (32, 33).
Most systemic gene therapy approaches for MPS VII (re-
viewed in ref. 34) were designed to allow modified cells to secrete
enzyme into the blood. Hepatic gene therapy with MLV-based
RV (17), lentiviral-based RV (35), adeno-associated virus
(AAV) vectors (36–38), or adenoviral vectors (39, 40) allowed
the liver to secrete the large (300 kDa) GUSB protein into the
blood in mice, and resulted in substantial clinical benefit. Gene
therapy of muscle with AAV vectors (34), or with fibroblasts
using different approaches (41, 42), resulted in lower serum
GUSB activity than liver-directed gene therapy in mice. For the
RV-treated dogs, GUSB activity in liver, serum, and other
organs was similar to the highest long-term (6 months) ex-
pression reported previously in MPS VII mice with gene therapy
(37). The GUSB activity in the HGFRV-treated dog exceeded
that reported previously in any animal model. In contrast,
neonatal i.v. injection of an AAV vector expressing cGUSB or
hGUSB from the CMV--actin promoter failed to result in
significant levels of expression in MPS VII dogs for reasons that
are unclear (M. Sands and M.E.H., unpublished data). Although
ex vivo gene therapy of fibroblasts resulted in low-level expres-
sion and improvements in pathology in the liver in MPS VII dogs,
there was no improvement in clinical features (43).
In this study, the average mannose 6-phosphorylated-GUSB
in serum was 32 unitsml for the RV-treated dogs. Because the
plasma volume in liters is 4% of the body weight in kg, and the
half-life of lysosomal enzymes in blood of large animals (10, 11)
or humans (13–15) is less than 1 h, it can be calculated that at
least 640 units of phosphorylated GUSB activity per kg is
secreted into the blood every hour, or 107,520 unitskgweek in
the RV-treated dogs. This is similar to the dose used for ERT in
humans with MPS I (125,000 unitskgweek; ref. 13). The
HGFRV-treated dog is calculated to secrete 12,000,000 units
kgweek. No antibodies were produced to the cGUSB (not
shown), and the absence of a cytotoxic T lymphocyte response
was inferred from the stable expression from the liver. The lack
of an immune response may be because wild-type GUSB differs
at only one position from the mutant protein. A single amino
acid change should allow most of the epitopes of the protein to
be presented during development and result in tolerization.
Alternatively, this lack may be due to performing gene therapy
at an age when the immune system was relatively immature.
Implications for Gene Therapy. The prevention of abnormalities in
growth, mobility, and many bone manifestations resemble what
was observed when BMT or high-dose ERT were performed
relatively early in life in MPS VII mice (9), or in large animals
(10–12) and humans (13) with MPS. The failure to prevent some
aspects of bone disease was seen with all treatments, and may be
due to abnormal bone formation in utero or the inability of
GUSB to reach some sites. Our gene therapy approach almost
completely prevented cardiovascular disease, a major cause of
death in patients with MPS, and corneal clouding was markedly
reduced. In contrast, some animals and patients that receive
ERT or BMT have only partial reductions in cardiovascular
disease and corneal clouding (13, 24–29, 44), which may be due
in part to the later age of treatment. Two RV-treated dogs had
low (1.5% of normal) GUSB enzyme activity and reductions in
cytoplasmic vaculation in the brain at 6 months (K.P.P. and
M.E.H., unpublished work), and all treated dogs appeared to be
neurologically normal throughout the study period. The enzyme
activity in the brain may have been taken up from blood before
the formation of the blood—brain barrier, because in MPS VII
mice enzyme can reach the brain if injected within 2 weeks after
birth (9). We remain concerned, however, that this systemic gene
therapy approach may not result in sustained improvements in
the pathological manifestations of MPS VII in the brain. Brain
pathology and neurological function will need to be evaluated
long-term in these dogs.
The clinical effect on heart, joint, and eye abnormalities was
similar for the RV- and HGFRV-treated dogs, suggesting that
achieving near-normal serum GUSB levels at an early age is
sufficient to prevent these manifestations. Neonatal humans
should have sufficient hepatocyte replication for gene transfer,
because they grow rapidly. Although currently most patients with
MPS are not diagnosed at birth, implementation of newborn
screening (45) may help to identify newborns with LSD in the
Fig. 3. Effect of RV-mediated gene therapy on the eye. (A) Fundus. The fundus of a normal dog (Normal) at 6 months (6M), an untreated MPS VII dog (Affected)
at 4 months, an RV-treated MPS VII dog (RV; M1332) at 8 months, and the HGFRV-treated MPS VII dog (HGFRV; M1287) at 11 months. Arrows identify the blood
vessels in the retina, which are indistinct in the affected dog. (B) Aqueous humor GUSB. Aqueous humor was aspirated from normal dogs at 6–10 months (n
5), untreated affected dogs at 6–7 months (n  4), RV-treated dogs at 6–10 months (n  5), and the HGFRV-treated dog at 13 months (n  1) and the GUSB
activity in unitsml determined and plotted as the average  SEM.
Fig. 4. Effect of RV-mediated gene therapy on the mitral valve. Echocardio-
grams were evaluated at 8–9 months after birth for normal (n 2), untreated
affected (n  5), and RV-treated dogs (n  3), and at 12 months for the
HGFRV-treated dog (n  1). The intensity of a murmur of mitral valve
regurgitation (MRMR) was scored from 0 (none) to 5 (most severe). The
severity of mitral valve regurgitation (MR) on echocardiography was scored
from 0 (normal) to 3 (severe regurgitation), and the degree of mitral valve
thickening on echocardiography was scored from 0 (normal) to 3 (markedly
thickened). The P value obtained from statistical comparisons between the
untreated affected and the RV-treated MPS VII dogs is shown.
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future. We are also testing whether gene transfer into older MPS
VII dogs can be achieved. This will likely require HGF or some
other treatment to augment hepatocyte replication, because
hepatocyte replication is very low in adult animals (17), and only
2.3% of hepatocytes were replicating at 6 days after birth in dogs
(19). Although the risks of germline transmission and insertional
mutagenesis are low, we will analyze animals for vector se-
quences in germ cells, and for neoplasia. Previously, we did not
detect RV sequences in the gonads following neonatal gene
transfer (19). If no adverse effects are observed, this approach
may be an effective and simple treatment for patients with LSD,
deficiencies of blood proteins such as hemophilia, or deficiencies
of other liver proteins.
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